Next Article in Journal
Design and Synthesis of Flavonoidal Ethers and Their Anti-Cancer Activity In Vitro
Next Article in Special Issue
Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art
Previous Article in Journal
Spin-Transport Tuning of Individual Magnetic Mn-Salophen Molecule via Chemical Adsorption
Previous Article in Special Issue
Formulation of Nanomicelles to Improve the Solubility and the Oral Absorption of Silymarin
Open AccessReview

Silymarin’s Inhibition and Treatment Effects for Alzheimer’s Disease

School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
*
Author to whom correspondence should be addressed.
Academic Editor: Dominique Delmas
Molecules 2019, 24(9), 1748; https://doi.org/10.3390/molecules24091748
Received: 28 March 2019 / Revised: 28 April 2019 / Accepted: 30 April 2019 / Published: 6 May 2019
(This article belongs to the Special Issue Silymarin and Derivatives: From Biosynthesis to Health Benefits)
As a longstanding problem, Alzheimer’s disease (AD) has stymied researchers in the medical field with its increasing incidence and enormous treatment difficulty. Silymarin has always been valued by researchers for its good efficacy and safety in treating liver disease. Recent studies have shown that silymarin also has good pharmacological activity in the nervous system, especially for the treatment of AD. Silymarin can control the production of Aβ by inhibiting the precursor substance of Aβ (β-amyloid precursor protein), and it can inhibit the polymerization of Aβ. Silymarin can also increase the acetylcholine content in the nervous system by inhibiting cholinesterase activity. At the same time, it also has the effect of resisting oxidative stress and the inflammatory response of the nervous system. These pharmacological activities contribute to the inhibition of the onset of AD. The good efficacy of silymarin on AD and its high safety and availability give it huge potential for the treatment of AD. View Full-Text
Keywords: silymarin; Alzheimer’s disease (AD); amyloid β-protein (Aβ); acetylcholine (ACh); oxidative stress; neuroinflammatory silymarin; Alzheimer’s disease (AD); amyloid β-protein (Aβ); acetylcholine (ACh); oxidative stress; neuroinflammatory
Show Figures

Figure 1

MDPI and ACS Style

Guo, H.; Cao, H.; Cui, X.; Zheng, W.; Wang, S.; Yu, J.; Chen, Z. Silymarin’s Inhibition and Treatment Effects for Alzheimer’s Disease. Molecules 2019, 24, 1748.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop